在中医络病理论指导下，立足于“从络治痹”的基本治则，课题以治疗风湿痹症最常用中药威灵仙为研究对象，在前期已从威灵仙分离得到43个化合物，并通过抗炎动物模型和抑制环氧化酶，初步阐明威灵仙药效物质的研究基础上，结合现代医学类风湿关节炎（RA）血管新生研究成果，提出假说：具有祛风湿，通经络之功效的威灵仙，通过抑制RA滑膜血管新生，达到通络治痹之目的。.课题以抑制滑膜血管新生为切入点，拟考察单体化合物对人脐静脉内皮细胞（HUVEC）和类风湿关节炎滑膜细胞（RA-HFLS）细胞增殖、迁移、粘附、管腔形成能力，细胞因子表达的影响，揭示威灵仙通络治痹的物质基础；建立胶原诱导性大鼠关节炎（CIA）模型，从动物-组织-细胞因子-基因四个层次研究威灵仙对大鼠RA滑膜血管新生的影响，阐释威灵仙通络治痹的作用机制。

Radix and rhizoma clematidis (Clematis chinensis Osbeck.) is most commonly used traditional Chinese medicine for the treatment of “Bi-Syndrome” (rheumatism). Our previous phytochemical research investigation lead to isolation of 43 compounds. A preliminary effect based on the anti-inflammation by animal and anti-COX2 enzyme data showed this medicine has well curative effect on“Bi-Syndrome”, which inspire us to further explore its effective substances and mechanism. So, with the guidance of “collateral disease” theory and “Bi-Syndrome” therapeutic rule of dredge the collaterals, and combine with modern research achievements of RA synovial angiogenesis, we hypothesis that the function “ dredge the collaterals and treat Bi –Syndrome” of Radix and radix clematidis is realized by inhibiting synovial angiogenesis.. In this research, we take the inhibiting synovial angiogenesis as the breakthrough point, further screen our previously isolated 43 bioactive compounds by proliferation, migration, adhesion and lumen formed experiments of blood umbilical vein endothelial cells (HUVEC) and RA synovial fibroblasts (RA-HFLS ), and evaluate their effects on related cytokine expression, to explore effective substances of radix clematidis. Simultaneously, a CIA rat arthritis model will be applied, and animal physiology, tissue lesions, cytokine and gene expression will be investigated, so as to elucidate its “dredge the collaterals and treat Bi –Syndrome” mechanism.